Study Group: Oncologists (Canada)(?)

It is an anomaly that people who have access to their personal financial information, cannot at present have the easy access to their health information. In fact, it is the patient's right to request a copy of thier health information. So, strictly speaking, health care providers are obliged to share...

The data for up front myeloma is promising but it has not been compared head to head against other promising novel therapies ( ie Revlimid) nor head to head with Melphalan, prednisone plus thalidomide. The MPT regimen has been demonstrated in a number of randomized trials to be superior to Melphalan...

This acceptance implies that the drug has the potential for widespread use in relapsed low grade NHL . However,there are some provisos to the acceptance by a wide audience of physcians. The low toxicity rate and ease of delivery make this drug very attractive to use as do the high response rates...

Re: MKC-1 in Canada I beieve that it will lilely turn out that this drug, like many others in the pipeleine presently, will add little to change outcome in leukemia. There is no mention here about what type of leukemia this is being trialed in, but if it is AML , there are other agents which I...

1) the data as presented so far is based on a small number of subjects 2) no data has yet been presented that it can actually change outcome in disease of any kind 3) no data is yet available of the cost utility of this technology